Evaxion A (EVAX) Income from Continuing Operations (2020 - 2026)
Evaxion A posted quarterly Income from Continuing Operations of 3398000.0 for Q1 2026, down 73.01% year-on-year from 12591833.96 in Q1 2025, and down 264.2% on a QoQ basis from 933000.0 in Q4 2025.
Evaxion A (EVAX) has 7 years of Income from Continuing Operations data on file, last reported at 3398000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 73.01% year-over-year to 3398000.0; the trailing twelve-month figure through Mar 2026 stood at 2745000.0 (up 81.54% YoY), and the FY2025 full-year result was 9523000.0, up 21.58% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 3398000.0, down from 933000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 6807000.0 in Q3 2025 and bottomed at 7218000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 5122000.0 (2022), against an average of 3839588.24.
- Peak annual rise in Income from Continuing Operations reached 420.03% in 2025, while the deepest fall reached 359.1% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 7218000.0 in 2022, then jumped by 32.43% to 4877000.0 in 2023, then grew by 14.31% to 4179000.0 in 2024, then surged by 77.67% to 933000.0 in 2025, then tumbled by 264.2% to 3398000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3398000.0 (Q1 2026), 933000.0 (Q4 2025), and 6807000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -453.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | -933,000.00 |
| Sep 30, 2025 | 6.81 Mn |
| Jun 30, 2025 | -5.22 Mn |
| Mar 31, 2025 | -1.96 Mn |
| Dec 31, 2024 | -4.18 Mn |
| Sep 30, 2024 | -2.13 Mn |
| Jun 30, 2024 | -6.60 Mn |
| Mar 31, 2024 | 758,000.00 |
| Dec 31, 2023 | -4.88 Mn |
| Sep 30, 2023 | -6.07 Mn |
| Jun 30, 2023 | -6.13 Mn |
| Mar 31, 2023 | -6.63 Mn |
| Dec 31, 2022 | -7.22 Mn |
| Sep 30, 2022 | -6.09 Mn |
| Jun 30, 2022 | -5.12 Mn |
| Mar 31, 2022 | -6.29 Mn |
| Dec 31, 2021 | -5.72 Mn |
| Sep 30, 2021 | -6.10 Mn |
| Jun 30, 2021 | -8.16 Mn |
| Mar 31, 2021 | -4.91 Mn |
| Dec 31, 2020 | -5.28 Mn |
| Sep 30, 2020 | -5.17 Mn |
| Jun 30, 2020 | -4.23 Mn |
| Mar 31, 2020 | -3.46 Mn |